SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Apple Turns 50: From Garage Startup to AI Crossroads 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
PITTSBURGH, Sept. 07, 2017 -- Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the development of innovative therapeutics for the treatment of Alzheimer’s disease and other neurocognitive disorders, announced that President & CEO Kenneth I. Moch will participate in the Mizuho Biotechnology Conference: CNS Deep Management Day on September 19, 2017 at the Langham Boston Hotel.
The clinical status of Cognition’s small molecule drug candidate, CT1812, will be among topics discussed by Mr. Moch. Patient dosing and follow-up has concluded in a Phase 1b/2 clinical study in patients with mild-to-moderate Alzheimer’s disease, and top-line results are expected to be announced in October. More complete results are anticipated to be presented during the 10th Clinical Trials on Alzheimer's Disease (CTAD) meeting taking place November 2-4, 2017.
To register for the Mizuho Securities conference and/or request a one-on-one meeting with Mr. Moch, please contact your Mizuho Securities corporate access representative.
About Cognition Therapeutics, Inc.
Cognition Therapeutics (CogRx) is a privately held biopharmaceutical company whose disease-relevant screening and novel chemistry platforms have produced a pipeline of disease modifying small molecule drug candidates which are being developed to treat Alzheimer’s disease and potentially other neurocognitive disorders. Cognition’s lead molecule, CT1812, is a proprietary first-in-class, orally available small molecule. This highly brain penetrant compound targets the sigma-2 receptor complex, displacing toxic beta amyloid oligomers from their binding sites on brain cells and clearing them into the cerebrospinal fluid. CT1812 has been shown in multiple Alzheimer’s disease models to stop memory loss. In Cognition’s recently completed Study COG0102, patients with mild-to-moderate Alzheimer’s disease were randomized to one of three doses of CT1812 or placebo, and dosed for 28 days to help evaluate the safety, tolerability and pharmacokinetic profile of CT1812. Detailed results of this Phase 1b/2 study are anticipated to be announced at the CTAD (Clinical Trials on Alzheimer's disease) meeting in Boston in November 2017. Additional information about Cognition may be found online at http://www.cogrx.com.
Cognition Therapeutics [email protected] Aline Sherwood Scienta Communications [email protected]
